Next Article in Journal
Predictive Models for Non-Alcoholic Fatty Liver Disease Diagnosis in Mexican Patients with Gallstone Disease: Sex-Specific Insights
Previous Article in Journal
OCT Angiography of the Retina and the Choroid in the Macula in Patients with Normal Tension Glaucoma and Primary Open Angle Glaucoma
 
 
Communication
Peer-Review Record

The Rationale and Design of the KOSovan Acute Coronary Syndrome (KOS-ACS) Registry

Diagnostics 2024, 14(14), 1486; https://doi.org/10.3390/diagnostics14141486
by Gani Bajraktari 1,2,3,*, Shpend Elezi 1,2, Ibadete Bytyci 1,2,3, Pranvera Ibrahimi 1,3, Genc Abdyli 1, Edita Pllana-Pruthi 1, Rona Karahoda 4, Arlind Batalli 1,2, Afrim Poniku 1,2, Mentor Shatri 1, Drilon Gashi 1, Artan Bajraktari 1, Faik Shatri 1 and Michael Y. Henein 3 on behalf of KOS-ACS Investigators
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Diagnostics 2024, 14(14), 1486; https://doi.org/10.3390/diagnostics14141486
Submission received: 29 March 2024 / Revised: 23 April 2024 / Accepted: 23 April 2024 / Published: 11 July 2024
(This article belongs to the Section Pathology and Molecular Diagnostics)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

Bajraktari et al. adequately describe the purpose of their register in this communication. The article is well written and outlines how the register will be developed and edited.  It certainly does not add anything new to the current literature, but provides a good perspective on how a register should be developed.

However, I have a few minor points that should be implemented:

1. figures 2 and 3 described in the article are not present, so they should be added

2. An accurate list of the data that will be collected should be provided (also as supplementary material) with the article

3. A list of participating centres should be given

 

Author Response

Response to Reviewer 1

 

Bajraktari et al. adequately describe the purpose of their register in this communication. The article is well written and outlines how the register will be developed and edited.  It certainly does not add anything new to the current literature, but provides a good perspective on how a register should be developed.

However, I have a few minor points that should be implemented:

  1. Figures 2 and 3 described in the article are not present, so they should be added

Response:

Thank you for your suggestion. It was an error during the uploading these figures, which now we included.

 

  1. An accurate list of the data that will be collected should be provided (also as supplementary material) with the article

Response:

Thank you for your suggestion. We now included it as a supplementary material.

 

  1. A list of participating centers should be given

Response:

Thank you for your suggestion. We now included the list of centers as a supplementary material.

Reviewer 2 Report

Comments and Suggestions for Authors

In this manuscript, Bajraktari et al. describe the rationale for the design of a registry in Kosovo, the first of its kind, for acute coronary disease.  This is a very noble undertaking and it will be exciting to see the development of this in the future.  This reviewer had one question.  Regarding the construction of the registry, have the authors thought about building a biobank with the corresponding samples?  Collecting multiple sample types (e.g. whole blood, serum, plasma, tissues) from these patients along with the registry information on disease type, treatment, demographics, etc. will provide an important and significant tool for future research and clinical studies.

Author Response

Response to Reviewer 2

 

In this manuscript, Bajraktari et al. describe the rationale for the design of a registry in Kosovo, the first of its kind, for acute coronary disease.  This is a very noble undertaking and it will be exciting to see the development of this in the future. 

 

This reviewer had one question.  Regarding the construction of the registry, have the authors thought about building a biobank with the corresponding samples?  Collecting multiple sample types (e.g. whole blood, serum, plasma, tissues) from these patients along with the registry information on disease type, treatment, demographics, etc. will provide an important and significant tool for future research and clinical studies.

Response:

We will collect the blood samples for biobank, but this belongs to another joint project that is waiting for the Ethics decision.

Back to TopTop